Agrochemicals company Sharda Cropchem announced Q2FY26 results Revenue: Rs 929.1 crore compared to Rs 776.9 crore during Q2FY25, change 20%. EBITDA: Rs 138.9 crore compared to Rs 81.3 crore during Q2FY25, change 71%. EBITDA Margin: 15.0% for Q2FY26. PAT: Rs 74.4 crore compared to Rs 42.4 crore during Q2FY25, change 75%. Ramprakash Bubna, Chairman & MD, said: “In Q2FY26, we delivered robust revenue growth of 20% YoY to Rs 929 crore, mainly driven by volumes. NAFTA and Europe remains a key contributors in both volume and value terms. With input costs stabilizing and improving price dynamics, Gross Margins has expanded by 690 basis points to 34.5% and we expect GP Margins to remain in a similar range going ahead. We expect prices to go up going forward. EBITDA has grown by 71% to Rs ~139 crore with EBITDA Margins at 15.0% (improved by 450 bps on Y-o-Y basis). For FY26, we are on track to maintain healthy EBITDA margins in the range of 15–18%. We remain committed to accelerating product registrations in FY26, supported by a planned capital expenditure of Rs 450–500 crore. Our strong registration pipeline of 1,068 underscores our resilience and sustained growth focus, positioning us well for the long term.” Result PDF
Agrochemicals company Sharda Cropchem announced Q1FY26 results Revenue: Rs 984.8 crore compared to Rs 785.1 crore during Q1FY25, change 25%. Gross Profit: Rs 349.2 crore compared to Rs 228.9 crore during Q1FY25, change 53%. Gross Profit Margin: 35.5% for Q1FY26. EBITDA: Rs 142.2 crore compared to Rs 85.4 crore during Q1FY25, change 67%. EBITDA Margin: 14.4% for Q1FY26. PAT: Rs 142.8 crore compared to Rs 27.3 crore during Q1FY25, change 424%. Ramprakash Bubna, Chairman & MD, said: “In Q1FY26, we recorded strong volume growth of ~13%, with revenues rising ~25% YoY to Rs 985 crore. This performance was driven by a global demand revival and improved pricing. Europe remains a key contributor in both volume and value terms. With input costs stabilizing, our Gross Margins has expanded by 630 basis points to 35.5% and we expect GP Margins to remain in a similar range going ahead. EBITDA has grown by 67% to Rs 142 crore with EBITDA Margins at 14.4%. We remain focused on increasing our product registrations in FY26, with planned capex of ~Rs 400-450 crore. Our strong pipeline of registrations reflects both our resilience and unwavering commitment to growth, laying a strong foundation for sustained future progress. For FY26, we aim to grow our topline by ~15% while maintaining healthy EBITDA Margins in the range of 15–18%.” Result PDF